2015 Newsroom

Keyword Search
 
2014 | 2013 | 2012
DateTitle 
05/28/15Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB) at the European Society of Human Genetics Annual Meeting 2015
Highlights in vitro Pre-Clinical Data for Novel Gene-Therapy Drug Candidate for Treatment of RDEB—a Rare, Congenital, Devastating Skin DiseaseEXTON, Pa. and GERMANTOWN, Md., May 28, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, toget... 
Printer Friendly Version
05/26/15Intrexon to Present at the Jefferies 2015 Global Healthcare Conference
GERMANTOWN, Md., May 26, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that Gregory Frost, Ph.D., Senior Vice President and Head of Intrexon's Health Sector, will present at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3rd, at 1:30 p.m. Eastern Time at the Grand Hyatt in New York City. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create... 
Printer Friendly Version
05/11/15Intrexon Announces First Quarter 2015 Financial Results
- Net income of $27.1 million or $0.26 per basic share - - Adjusted EBITDA of $(11.3 million) or $(0.11) per basic share - - Declares Special Stock Dividend of ZIOPHARM Shares - GERMANTOWN, Md., May 11, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its first quarter results for 2015.  Business Highlights and Recent Developments: Entered into an exclusive collaboration and license agreement with the biopharmaceutical bu... 
Printer Friendly Version
05/04/15Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015
GERMANTOWN, Md., May 4, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) today announced it will release first quarter 2015 financial results after the market closes on May 11, 2015.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-888-346-3959 (Domestic US) and 1-412-902-4262 (International) and asking to join the "Intrexon Conference Call."  Participants may a... 
Printer Friendly Version
04/30/15Intrexon to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
GERMANTOWN, Md., April 30, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that Randal J. Kirk, Chairman and Chief Executive Officer, and Krish Krishnan, Chief Operating Officer, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12th, at 8:40 a.m. Pacific Standard Time at Encore at the Wynn, Las Vegas, Nevada. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic... 
Printer Friendly Version
04/20/15Intrexon Completes Acquisition of Okanagan Specialty Fruits
Healthy Produce Choices for Consumers With Benefits Across Entire Supply Chain GERMANTOWN, Md., April 20, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has completed the acquisition of Okanagan Specialty Fruits (OSF), the pioneering agricultural company behind the Arctic® apple, the world's first non-browning apple without the use of any flavor-altering chemical or antioxidant additives. OSF's vision and ground-breaking effort in re... 
Printer Friendly Version
04/15/15Driving Sustainable Agriculture through Improved Qualities in Eucalyptus and Poplar Trees
Intrexon and FuturaGene Collaborate to Develop Unique Attributes and Agronomic Properties in Significant Plant Species GERMANTOWN, Md. and SAO PAULO, April 15, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and FuturaGene Group, a wholly owned subsidiary of Suzano Papel e Celulose S.A., the second largest producer of eucalyptus pulp in the world, today announced they have entered into an exclusive collaboration to increase biomass in eucalyptus and pop... 
Printer Friendly Version
03/30/15ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono
BOSTON and GERMANTOWN, Md., March 30, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) and Intrexon Corporation (NYSE:XON) today announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, including upfront payment, ... 
Printer Friendly Version
03/30/15Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
- Chimeric Antigen Receptor T-cell (CAR-T) therapy enhances Merck Serono's R&D technology portfolio in immuno-oncology - Collaboration and license agreement will focus on developing a next generation CAR-T platform to generate several drug candidates GERMANTOWN, Md., March 30, 2015  /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced an exclusive strategic ... 
Printer Friendly Version
03/02/15Intrexon Announces Fourth Quarter and Full Year 2014 Financial Results
Quarterly Net Income of $18.8M or $0.19/share on 335% Revenue Growth FY2014 Adjusted EBITDA Positive, Achieving Key Management Goal GERMANTOWN, Md., March 2, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced its fourth quarter and full year results for 2014.  Business Highlights and Recent Developments: Acquired ActoGeniX, a European clinical stage biopharmaceutical company forging a new frontier in cellular therapeutics and ... 
Printer Friendly Version
02/27/15Intrexon to Acquire Okanagan Specialty Fruits
Increasing Access to Convenient, Fresh Produce Choices for Consumers GERMANTOWN, Md. and SUMMERLAND, British Columbia, Feb. 27, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has entered into an agreement to acquire Okanagan Specialty Fruits (OSF), the pioneering agricultural company behind the Arctic® apple, the world's first non-browning apple. Through the acquisition, Intrexon expands its food programs to include trees yielding fr... 
Printer Friendly Version
02/23/15Intrexon to Announce Fourth Quarter and Full Year 2014 Financial Results on Monday, March 2, 2015
GERMANTOWN, Md., Feb. 23, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) today announced it will release fourth quarter and full year 2014 financial results after the market closes on March 2, 2015.  The Company will host a conference call that day at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-888-346-3959 (Domestic US) and 1-412-902-4262 (International) and asking to join the "Intrexon Conference Call."  Pa... 
Printer Friendly Version
02/13/15Living Biofactories in Your Prescription Bottle?
Belgium's ActoGeniX to Join Intrexon Bringing New Generation of Orally Delivered Biotherapeutics GERMANTOWN, Md. and GHENT, Belgium, Feb. 13, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has entered into a definitive agreement to acquire ActoGeniX, a European clinical stage biopharmaceutical company forging a new frontier in cellular therapeutics.  The proprietary TopAct™ platform developed by ActoGeniX enables the molecular eng... 
Printer Friendly Version
01/27/15Intrexon Announces Closing of $116 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
GERMANTOWN, Md., Jan. 27, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today the closing of its previously announced public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 562,500 shares of common stock at the public offering price of $27.00 per share. The exercise of the underwriters' option brought the total number of shares of common stock sold by Intrexon to 4,312,500 sha... 
Printer Friendly Version
01/26/15Intrexon to Acquire Remaining Stake in Exemplar Genetics
Intrexon Collaborators Obtain Access to Premier Pipeline of Large Animal Research Models and Custom Animal Development GERMANTOWN, Md. and SIOUX CENTER, Iowa, Jan. 26, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced it has launched a tender offer to acquire the remaining stake in Exemplar Genetics, a company committed to enabling the study of life-threatening human diseases.  Utilizing its proprietary technologies in animal genetics, Exe... 
Printer Friendly Version
01/21/15Intrexon Prices Public Offering of Common Stock
GERMANTOWN, Md., Jan. 21, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has priced its previously announced underwritten public offering of common stock consisting of 3,750,000 shares at a public offering price of $27.00 per share.  Gross proceeds to Intrexon from this offering are expected to be approximately $101.25 million and Intrexon intends to use the net proceeds from this offering for general corporate purposes as well as fo... 
Printer Friendly Version
01/20/15Intrexon Announces Proposed Public Offering of Common Stock
GERMANTOWN, Md., Jan. 20, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today it has commenced an underwritten public offering of up to $150 million of shares of its common stock.  Intrexon intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of the common stock offered in the public offering.  All of the shares in the offering will be sold by Intrexon. J.P. Morgan and BofA Merrill Lynch are actin... 
Printer Friendly Version
01/13/15Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact
Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies Combined Technologies to Leapfrog Clinical Pipeline of Next Generation Therapies Using Synthetic and Personalized Immunology GERMANTOWN, Md., BOSTON, and HOUSTON, Jan. 13, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (NASDAQ: ZIOP), today announced a ... 
Printer Friendly Version
01/06/15Intrexon to Present at the 2015 J.P. Morgan Healthcare Conference
GERMANTOWN, Md., Jan. 6, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14th, at 8:30 a.m. Pacific Standard Time at the Westin St. Francis in San Francisco. About Intrexon Corporation Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in... 
Printer Friendly Version